Sci Rep:肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果

2020-10-11 AlexYang MedSci原创

最近,有研究人员进行了一项回顾性研究,评估了肌肉浸润性或转移性膀胱癌(MIBC/mBC)化疗治疗患者的真实世界肿瘤学结果,并将结果与RCTs和其他队列的数据进行了比较。

最近,有研究人员进行了一项回顾性研究,评估了肌肉浸润性或转移性膀胱癌(MIBC/mBC)化疗治疗患者的真实世界肿瘤学结果,并将结果与RCTs和其他队列的数据进行了比较。

研究包括了1578名诊断患者,其中470名(30%)患有MIBC/mBC。单独的RC(47个月)、一线化疗(13个月)和二线化疗(7个月)和复发疾病化疗(8个月)的总生存中位数(mOS)与之前文献报道的相似。只有9%的患者进行了新辅助和诱导化疗(NAIC)治疗,而且往往是在疾病状态不佳的患者中,所以与文献报道的相比,mOS较低(分别为35个月和20个月)。另外,接受化疗的患者在治疗过程中有许多障碍,且在NAIC、一线治疗、RC后挽救治疗和二线治疗中,分别仅有50%、13%、18%和7%的患者完成了整个计划的化疗。真实世界数据显示,RC前的NAIC利用率不足。化疗期间的高频障碍导致很多患者需要减量或提前终止治疗,导致治疗反应不佳。尽管RCTs和现实世界患者的治疗效果相当类似,但基线特征和治疗模式存在较大差异。

肌层浸润或转移性膀胱癌患者的总生存

最后,研究人员指出,对真实世界数据的回顾性研究应该可以为老年和 "不适合 "的患者提供化疗有效性的证据。

原始出处:

Daan J. Reesink, Ewoudt M. W. van de Garde, Bas. J. M. Peters et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    已看,还可以。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
    2020-10-11 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
    2020-10-11 ms6646080209544003

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1898855, encodeId=15ae189885548, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Dec 12 13:44:12 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954954, encodeId=fdb2954954c6, content=已看,还可以。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 16:24:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Oct 13 05:44:12 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039994, encodeId=f706103999444, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Oct 11 17:44:12 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891281, encodeId=7b0c891281f0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibwO8MoUKfv2u6gPr01aBTib6H929mPb5CUrIlEWBlKoe6K0lUkNEsmvQ2c2kiatf0IWv6VPpfsGaTSwzS3fzibwRg/132, createdBy=6b0b5191085, createdName=ms6646080209544003, createdTime=Sun Oct 11 16:07:45 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891262, encodeId=70bc89126250, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 11 14:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=)]
    2020-10-11 ms3000000449926787

    学习了

    0

相关资讯

Ann Oncol:曲拉西利布可改善对患者化疗的耐受性

化疗诱导的造血干细胞和祖细胞(HSPC)损伤导致多系骨髓抑制。Trilaciclib是一种正在开发的静脉注射CDK4/6抑制剂,可在化疗期间主动保护HSPC和免疫系统功能(骨髓抑制)。临床前,tril

J Clin Oncol:2000年-2015年经典霍奇金淋巴瘤的死亡率变化

在广泛应用阿霉素、博来霉素、长春新碱和达卡巴嗪,放疗应用减少的时代,经典霍奇金淋巴瘤(cHL)患者的死亡率未有明确的统计。

CSCO于振涛:食管癌新辅助治疗研究与展望

相比国际领域,国内食管癌研究稍显落后,相信我们未来食管癌新辅助治疗研究会有大的突破,能够打开我们精准的食管癌治疗的大门。

“化疗导致恶心呕吐是小事忍忍就好?”……化疗的这些坑你踩到了吗?

要说化疗有多辛苦?没经历过的人肯定不知道。很多人谈到化疗就认为是会吐得不行,并且没办法预防和控制,其实,这都是关于化疗的误区。

Prostate Cancer P D:未治疗转移前列腺癌前期化疗的生存率研究

基于临床试验数据,前期化疗可延长转移性、激素敏感性前列腺癌(mHSPC)男性的总生存。最近,有研究人员在一个真实世界的队列中评估了前期化疗与mHSPC男性总生存之间的关联。

Neoplasia :公布PARP抑制剂晚期卵巢2期临床数据,有望为患者开启“去化疗”治疗新时代

在我国,卵巢癌年发病率居女性生殖系统肿瘤第3位,位于子宫颈癌和子宫体恶性肿瘤之后,呈逐年上升的趋势,而死亡率则位居女性生殖道恶性肿瘤之首,是严重威胁女性健康的恶性肿瘤。